CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to BMY

BMS-986489 (BMS-986012+Nivolumab)

Phase 3
Bristol-Myers Squibb Company (BMY)

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q3 '27
BMYPhase 3

BMS-986489 (BMS-986012+Nivolumab) Phase 3 Est. Readout

BMS-986489 (BMS-986012+Nivolumab)
Q3 2027~Q
CT.gov
00%
Competitive Landscape

1 competitor in Extensive-Stage Small Cell Lung Cancer

View Full Landscape
Drug Information

Target Indication

Extensive-Stage Small Cell Lung Cancer

Clinical Trial

NCT06646276

Last updated: 7/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.